News
AbbVie has entered into a $700 million licensing agreement with IGI Therapeutics to co-develop ISB 2001, a promising ...
A new report by the U.N. AIDS agency says the sudden withdrawal of U.S. funding has caused a “systemic shock” to the global effort against AIDS and HIV. Years of American-led investment into AIDS ...
Carlene Pavlos, executive director of the Massachusetts Public Health Association, one of the plaintiffs, said in a statement ...
US biopharma company AbbVie has inked a $700 million deal with IGI Therapeutics to develop and sell ISB 2001, an experimental drug for blood cancer.
Glenmark Share Price: Shares of Glenmark Pharmaceuticals Ltd surged 10 per cent in early trade on Friday, scaling a new ...
The deal also entails $1.23 billion in milestone payments. While Glenmark unit IGI will retain rights for India and emerging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results